Distillate Capital Partners LLC Sells 27,830 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Distillate Capital Partners LLC lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 18.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 123,319 shares of the specialty pharmaceutical company's stock after selling 27,830 shares during the period. Distillate Capital Partners LLC owned approximately 0.20% of Jazz Pharmaceuticals worth $15,187,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Rockefeller Capital Management L.P. lifted its position in shares of Jazz Pharmaceuticals by 1.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 250,410 shares of the specialty pharmaceutical company's stock worth $30,838,000 after acquiring an additional 4,006 shares in the last quarter. Sterling Capital Management LLC lifted its holdings in Jazz Pharmaceuticals by 9.0% during the 4th quarter. Sterling Capital Management LLC now owns 15,215 shares of the specialty pharmaceutical company's stock worth $1,874,000 after purchasing an additional 1,260 shares in the last quarter. LSV Asset Management boosted its stake in Jazz Pharmaceuticals by 1.5% in the 4th quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock worth $311,699,000 after purchasing an additional 37,108 shares during the period. Bessemer Group Inc. grew its holdings in Jazz Pharmaceuticals by 0.3% during the 4th quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock valued at $3,317,000 after buying an additional 92 shares in the last quarter. Finally, Faithward Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 3.3% during the fourth quarter. Faithward Advisors LLC now owns 14,323 shares of the specialty pharmaceutical company's stock valued at $1,764,000 after buying an additional 460 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company's stock, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares of the company's stock, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,023,305 in the last ninety days. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Trading Up 1.2 %

Shares of NASDAQ JAZZ traded up $1.23 during midday trading on Thursday, reaching $102.78. The company had a trading volume of 995,175 shares, compared to its average volume of 787,720. The stock has a market cap of $6.24 billion, a PE ratio of 14.48, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The firm's fifty day moving average price is $128.56 and its 200-day moving average price is $122.42. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Analysts Set New Price Targets

Several brokerages recently commented on JAZZ. HC Wainwright boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Royal Bank of Canada reduced their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Piper Sandler reiterated an "overweight" rating and issued a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Morgan Stanley restated an "overweight" rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Finally, JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.